Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845299 · ClinicalTrials.gov registry record · Phase 2
Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
A Phase 2 study, sponsored by Mati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00845299 is a Phase 2 study that has completed, run by Mati Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT00845299, a Phase 2 study, has completed, sponsored by Mati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of artificial tears preserved with Benzalkonium Chloride (AT-BAK) on the IOP response to the L-PPDS and to evaluate the safety of the L-PPDS in subjects with OH or OAG following treatment.
Interventions
- DRUG Latanoprost punctal plug
- DRUG artificial tears preserved with Benzalkonium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845299
The ClinicalTrials.gov registry entry for NCT00845299 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mati Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Latanoprost punctal plug is the first listed.
NCT00845299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845299 about?
NCT00845299 is a clinical study titled "Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma". The purpose of this study is to determine the effect of artificial tears preserved with Benzalkonium Chloride (AT-BAK) on the IOP response to the L-PPDS and to evaluate the safety of the L-PPDS in subjects with OH or OAG following treatment.
What is the current status of trial NCT00845299?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2009-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00845299?
The interventions under investigation include: Latanoprost punctal plug (DRUG), artificial tears preserved with Benzalkonium Chloride (DRUG).
Who is sponsoring clinical trial NCT00845299?
This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.